Study to Assess the Safety and Effect of Repeated Administration of Granulocyte Colony-Stimulating Factor (G-CSF; Filgrastim) on Hot Flashes and Other Vasomotor Symptoms of Menopause in Postmenopausal Women
Phase of Trial: Phase I
Latest Information Update: 15 Nov 2019
Price : $35 *
At a glance
- Drugs Filgrastim (Primary)
- Indications Menopausal syndrome
- Focus Adverse reactions
- Sponsors MenoGeniX
- 12 Nov 2019 Planned End Date changed from 6 Sep 2019 to 6 Sep 2020.
- 12 Nov 2019 Planned primary completion date changed from 6 Aug 2019 to 6 Aug 2020.
- 27 Aug 2018 New trial record